首页 › 基金 › Venrock Adviser, LLC › DMRA
Venrock Adviser, LLC 对 DMRA 的持仓历史
DAMORA THERAPEUTICS INC · 医疗保健
Venrock Adviser, LLC 在 Q3 2026 的 13F 申报中披露持有 DMRA(DAMORA THERAPEUTICS INC)3,603,595 股,市值约 US$76.7M,约占其申报组合的 3.73%,在其申报持仓中市值排名第 7 位。 Venrock Adviser, LLC 最近 3 个申报季度中有 3 个季度披露了 DMRA 持仓,最早可追溯至 Q1 2026。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
Venrock Adviser, LLC 对 DMRA 的持仓演变
Venrock Adviser, LLC 于 Q1 2026 首次披露 DMRA 持仓:3,603,595 股(约 US$93.3M)。 该持仓在 Q2 2026 达到峰值 3,603,595 股,市值约 US$93.7M。 在 3 次申报中,Venrock Adviser, LLC 的持股数量始终未变。 最近一期申报(Q3 2026)显示持股 3,603,595 股、市值约 US$76.7M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q1 2026 | 3.60M | $93.33M | 新进 |
| Q2 2026 | 3.60M | $93.73M | 持有 |
| Q3 2026 | 3.60M | $76.68M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 DMRA 与 13F 数据
DMRA(DAMORA THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 83 只申报持有 DMRA,申报仓位最大的包括:Fairmount Funds Management LLC (US$185.4M), Avoro Capital Advisors LLC (US$80.5M), FCPM III SERVICES B.V. (US$51.9M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 DMRA 的基金
- Fairmount Funds Management LLC 8.71M 股 · $185.41M · Q3 2026
- Avoro Capital Advisors LLC 3.78M 股 · $80.50M · Q3 2026
- FCPM III SERVICES B.V. 2.44M 股 · $51.94M · Q3 2026
- RA CAPITAL MANAGEMENT, L.P. 2.40M 股 · $51.07M · Q3 2026
- Remedium Capital Partners, LLC 2.05M 股 · $43.53M · Q3 2026
- Commodore Capital LP 1.94M 股 · $41.26M · Q3 2026
- Bellevue Group AG 1.92M 股 · $40.84M · Q3 2026
- BRAIDWELL LP 1.75M 股 · $37.19M · Q3 2026
- a16z Capital Management, L.L.C. 1.24M 股 · $26.31M · Q3 2026
- Siren, L.L.C. 900.00K 股 · $19.15M · Q3 2026
- Cormorant Asset Management, LP 800.00K 股 · $17.02M · Q3 2026
- STEMPOINT CAPITAL LP 506.07K 股 · $10.77M · Q3 2026
更多关于 Venrock Adviser, LLC
常见问题
How long has Venrock Adviser, LLC held DMRA?
Venrock Adviser, LLC has disclosed DMRA holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Venrock Adviser, LLC's current position in DMRA?
As of Q3 2026, Venrock Adviser, LLC holds 3.60M shares of DMRA (DAMORA THERAPEUTICS INC), valued at $76.68M, representing 3.73% of its reported portfolio and ranking #7.
Has Venrock Adviser, LLC been buying or selling DMRA?
In the latest 13F filing (Q3 2026), Venrock Adviser, LLC held unchanged its position in DMRA. The position peaked in Q2 2026 at 3.60M shares.
Which other funds hold DMRA?
Other major institutional holders of DMRA include Fairmount Funds Management LLC, Avoro Capital Advisors LLC, FCPM III SERVICES B.V., among 83 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.